Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Brain distributional kinetics of a novel MDM2 inhibitor SAR405838: Implications for use in brain tumor therapy.

Kim M, Laramy JK, Gampa G, Parrish KE, Brundage RC, Sarkaria JN, Elmquist WF.

Drug Metab Dispos. 2019 Oct 16. pii: dmd.119.088716. doi: 10.1124/dmd.119.088716. [Epub ahead of print]

2.

Estrogen-related receptor β activation and isoform shifting by cdc2-like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma.

Tiek DM, Khatib SA, Trepicchio CJ, Heckler MM, Divekar SD, Sarkaria JN, Glasgow E, Riggins RB.

FASEB J. 2019 Sep 28:fj201901075R. doi: 10.1096/fj.201901075R. [Epub ahead of print]

PMID:
31570001
3.

Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.

Tew BY, Legendre C, Schroeder MA, Triche T, Gooden GC, Huang Y, Butry L, Ma DJ, Johnson K, Martinez RA, Pierobon M, Petricoin EF, O'Shaughnessy J, Osborne C, Tapia C, Buckley DN, Glen J, Bernstein M, Sarkaria JN, Toms SA, Salhia B.

Neuro Oncol. 2019 Aug 21. pii: noz137. doi: 10.1093/neuonc/noz137. [Epub ahead of print]

PMID:
31433055
4.

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Guo G, Gong K, Puliyapaddamba VT, Panchani N, Pan E, Mukherjee B, Damanwalla Z, Bharia S, Hatanpaa KJ, Gerber DE, Mickey BE, Patel TR, Sarkaria JN, Zhao D, Burma S, Habib AA.

Neuro Oncol. 2019 Jul 31. pii: noz127. doi: 10.1093/neuonc/noz127. [Epub ahead of print]

PMID:
31363754
5.

Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.

Pedron S, Wolter GL, Chen JE, Laken SE, Sarkaria JN, Harley BAC.

Biomaterials. 2019 Oct;219:119371. doi: 10.1016/j.biomaterials.2019.119371. Epub 2019 Jul 19.

PMID:
31352310
6.

Molecular profiling of long-term IDH-wildtype glioblastoma survivors.

Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, Kolsky KL, Ida CM, Meyer FB, Lachance DH, Parney IJ, Kipp BR, Giannini C, Sulman EP, Jenkins RB, Eckel-Passow JE, Sarkaria JN.

Neuro Oncol. 2019 Nov 4;21(11):1458-1469. doi: 10.1093/neuonc/noz129.

PMID:
31346613
7.

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach.

Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR; ENDURES consortium.

Am J Clin Oncol. 2019 Aug;42(8):655-661. doi: 10.1097/COC.0000000000000564.

PMID:
31343422
8.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
9.

Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.

Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS.

Cancer Res. 2019 Sep 1;79(17):4331-4338. doi: 10.1158/0008-5472.CAN-18-3394. Epub 2019 Jul 4.

PMID:
31273061
10.

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):583. doi: 10.1007/s11060-019-03201-3.

11.

Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.

Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR.

Neuro Oncol. 2019 May 23. pii: noz090. doi: 10.1093/neuonc/noz090. [Epub ahead of print]

PMID:
31121035
12.

Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jul;143(3):573-581. doi: 10.1007/s11060-019-03194-z. Epub 2019 May 22. Erratum in: J Neurooncol. 2019 Jun 5;:.

PMID:
31119479
13.

Pathogenic Germ Line Variants in a Patient With Severe Toxicity From Breast Radiotherapy.

Wilhite TJ, Youland RS, Tian S, Finley RR, Sarkaria JN, Corbin KS.

Clin Breast Cancer. 2019 Jun;19(3):e400-e405. doi: 10.1016/j.clbc.2019.03.004. Epub 2019 Mar 28. No abstract available.

PMID:
31031124
14.

Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data.

Abdelmoula WM, Regan MS, Lopez BGC, Randall EC, Lawler S, Mladek AC, Nowicki MO, Marin BM, Agar JN, Swanson KR, Kapur T, Sarkaria JN, Wells W, Agar NYR.

Anal Chem. 2019 May 7;91(9):6206-6216. doi: 10.1021/acs.analchem.9b00854. Epub 2019 Apr 22.

PMID:
30932478
15.

Fluorescent reporter assays provide direct, accurate, quantitative measurements of MGMT status in human cells.

Nagel ZD, Beharry AA, Mazzucato P, Kitange GJ, Sarkaria JN, Kool ET, Samson LD.

PLoS One. 2019 Feb 27;14(2):e0208341. doi: 10.1371/journal.pone.0208341. eCollection 2019.

16.

PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN.

Front Oncol. 2019 Jan 22;8:670. doi: 10.3389/fonc.2018.00670. eCollection 2018.

17.

Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and Abcb1/Abcg2-Deficient Mice.

Kim M, Laramy JK, Mohammad AS, Talele S, Fisher J, Sarkaria JN, Elmquist WF.

Drug Metab Dispos. 2019 Apr;47(4):393-404. doi: 10.1124/dmd.118.084210. Epub 2019 Jan 31.

PMID:
30705084
18.

Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Mohammad AS, Parrish KE, Mladek AC, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2019 Mar;368(3):446-461. doi: 10.1124/jpet.118.253708. Epub 2019 Jan 8.

PMID:
30622172
19.

Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior.

Chen JE, Pedron S, Shyu P, Hu Y, Sarkaria JN, Harley BAC.

Front Mater. 2018 Jun;5. pii: 39. doi: 10.3389/fmats.2018.00039. Epub 2018 Jun 26.

20.

Drug and disease signature integration identifies synergistic combinations in glioblastoma.

Stathias V, Jermakowicz AM, Maloof ME, Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW, Volmar CH, Lyons NJ, Wahlestedt C, Graham RM, Ivan ME, Komotar RJ, Sarkaria JN, Subramanian A, Golub TR, Schürer SC, Ayad NG.

Nat Commun. 2018 Dec 14;9(1):5315. doi: 10.1038/s41467-018-07659-z.

21.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

22.

Quantifying the setup uncertainty of a stereotactic murine micro-image guided radiation therapy system.

Walb MC, Carlson BL, Sarkaria JN, Tryggestad EJ.

Br J Radiol. 2019 Mar;92(1095):20180487. doi: 10.1259/bjr.20180487. Epub 2018 Nov 14.

PMID:
30299986
23.

Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.

Unruh D, Mirkov S, Wray B, Drumm M, Lamano J, Li YD, Haider QF, Javier R, McCortney K, Saratsis A, Scholtens DM, Sarkaria JN, James CD, Horbinski C.

Clin Cancer Res. 2019 Jan 15;25(2):747-759. doi: 10.1158/1078-0432.CCR-18-1222. Epub 2018 Sep 28.

PMID:
30266764
24.

IGFBP6 controls the expansion of chemoresistant glioblastoma through paracrine IGF2/IGF-1R signaling.

Oliva CR, Halloran B, Hjelmeland AB, Vazquez A, Bailey SM, Sarkaria JN, Griguer CE.

Cell Commun Signal. 2018 Sep 19;16(1):61. doi: 10.1186/s12964-018-0273-7.

25.

ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.

Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.

Mol Cancer Ther. 2018 Nov;17(11):2462-2472. doi: 10.1158/1535-7163.MCT-18-0470. Epub 2018 Aug 30.

26.

Investigating Dependencies of Relative Biological Effectiveness for Proton Therapy in Cancer Cells.

Howard ME, Beltran C, Anderson S, Tseung WC, Sarkaria JN, Herman MG.

Int J Part Ther. 2018 Winter;4(3):12-22. doi: 10.14338/IJPT-17-00031.1. Epub 2018 Mar 21.

27.

Hypoxia-inducible factor 2α: a novel target in gliomas.

Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE.

Future Med Chem. 2018 Sep 1;10(18):2227-2236. doi: 10.4155/fmc-2018-0163. Epub 2018 Aug 9. Review.

28.

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine.

Jun HJ, Appleman VA, Wu HJ, Rose CM, Pineda JJ, Yeo AT, Delcuze B, Lee C, Gyuris A, Zhu H, Woolfenden S, Bronisz A, Nakano I, Chiocca EA, Bronson RT, Ligon KL, Sarkaria JN, Gygi SP, Michor F, Mitchison TJ, Charest A.

Nat Commun. 2018 Aug 6;9(1):3116. doi: 10.1038/s41467-018-05036-4.

29.

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.

Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, Kitange GJ, He L, Hu Z, Parney IF, Meyer FB, Giannini C, Sarkaria JN, Zhang Z.

Nat Commun. 2018 Jul 27;9(1):2949. doi: 10.1038/s41467-018-05373-4.

30.

Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.

Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF.

Pharm Res. 2018 Jul 12;35(9):177. doi: 10.1007/s11095-018-2455-9. Review.

31.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.

Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2018 Sep;17(9):1893-1901. doi: 10.1158/1535-7163.MCT-17-0600. Epub 2018 Jul 3.

32.

H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers.

Fang D, Gan H, Cheng L, Lee JH, Zhou H, Sarkaria JN, Daniels DJ, Zhang Z.

Elife. 2018 Jun 22;7. pii: e36696. doi: 10.7554/eLife.36696.

33.

Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.

Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, Weroha SJ, Jen J, Sarkaria JN, Galanis E.

J Natl Cancer Inst. 2018 Oct 1;110(10):1123-1132. doi: 10.1093/jnci/djy033.

34.

Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

Bristow RG, Alexander B, Baumann M, Bratman SV, Brown JM, Camphausen K, Choyke P, Citrin D, Contessa JN, Dicker A, Kirsch DG, Krause M, Le QT, Milosevic M, Morris ZS, Sarkaria JN, Sondel PM, Tran PT, Wilson GD, Willers H, Wong RKS, Harari PM.

Lancet Oncol. 2018 May;19(5):e240-e251. doi: 10.1016/S1470-2045(18)30096-2. Review.

PMID:
29726389
35.

Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.

Linninger A, Hartung GA, Liu BP, Mirkov S, Tangen K, Lukas RV, Unruh D, James CD, Sarkaria JN, Horbinski C.

Neuro Oncol. 2018 Aug 2;20(9):1197-1206. doi: 10.1093/neuonc/noy051.

36.

Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues.

Zhou D, Alver BM, Li S, Hlady RA, Thompson JJ, Schroeder MA, Lee JH, Qiu J, Schwartz PH, Sarkaria JN, Robertson KD.

Genome Biol. 2018 Mar 27;19(1):43. doi: 10.1186/s13059-018-1420-6.

37.

Presence of stromal cells in a bioengineered tumor microenvironment alters glioblastoma migration and response to STAT3 inhibition.

Herrera-Perez RM, Voytik-Harbin SL, Sarkaria JN, Pollok KE, Fishel ML, Rickus JL.

PLoS One. 2018 Mar 22;13(3):e0194183. doi: 10.1371/journal.pone.0194183. eCollection 2018.

38.

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival.

Lassak A, Dean M, Wyczechowska D, Wilk A, Marrero L, Trillo-Tinoco J, Boulares AH, Sarkaria JN, Del Valle L, Peruzzi F, Ochoa A, Reiss K.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00608-17. doi: 10.1128/MCB.00608-17. Print 2018 May 15.

39.

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.

Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF.

J Pharmacol Exp Ther. 2018 May;365(2):249-261. doi: 10.1124/jpet.117.246116. Epub 2018 Feb 12.

40.

Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, DePalatis L, Elmquist WF.

Drug Metab Dispos. 2018 May;46(5):658-666. doi: 10.1124/dmd.117.079194. Epub 2018 Feb 2.

41.

LPA signaling is regulated through the primary cilium: a novel target in glioblastoma.

Loskutov YV, Griffin CL, Marinak KM, Bobko A, Margaryan NV, Geldenhuys WJ, Sarkaria JN, Pugacheva EN.

Oncogene. 2018 Mar;37(11):1457-1471. doi: 10.1038/s41388-017-0049-3. Epub 2018 Jan 11.

42.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.

Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, Sarkaria JN.

Cancer. 2018 Apr 1;124(7):1455-1463. doi: 10.1002/cncr.31219. Epub 2018 Jan 3.

43.

Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics.

Pedron S, Polishetty H, Pritchard AM, Mahadik BP, Sarkaria JN, Harley BAC.

MRS Commun. 2017 Sep;7(3):442-449. doi: 10.1557/mrc.2017.85. Epub 2017 Sep 12.

44.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

45.

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.

Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, Giannini C, Burns TC, Kizilbash SH, Laramy JK, Swanson KR, Kaufmann TJ, Brown PD, Agar NYR, Galanis E, Buckner JC, Elmquist WF.

Neuro Oncol. 2018 Jan 22;20(2):184-191. doi: 10.1093/neuonc/nox175. Review.

46.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

47.

Real-Time Methylation-Specific Polymerase Chain Reaction for MGMT Promoter Methylation Clinical Testing in Glioblastoma: An Alternative Detection Method for a Heterogeneous Process.

Ida CM, Butz ML, Jenkins RB, Sarkaria JN, Kitange GJ, Giannini C, Kipp BR.

Am J Clin Pathol. 2017 Oct 1;148(4):296-307. doi: 10.1093/ajcp/aqx073.

PMID:
28967952
48.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

49.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

50.

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival.

Müller-Greven G, Carlin CR, Burgett ME, Ahluwalia MS, Lauko A, Nowacki AS, Herting CJ, Qadan MA, Bredel M, Toms SA, Lathia JD, Hambardzumyan D, Sarkaria JN, Hamerlik P, Gladson CL.

Clin Cancer Res. 2017 Nov 15;23(22):7059-7071. doi: 10.1158/1078-0432.CCR-17-0249. Epub 2017 Sep 14.

Supplemental Content

Loading ...
Support Center